Seragene Therapeutics

SeraGene has developed SG-001, a universal siRNA-based hemostatic agent aimed at treating a wide range of rare bleeding disorders. SG-001 is a first-in-class therapy that offers the convenience of monthly dosing, significantly reducing treatment burden while minimizing the risks of thrombosis and inhibitor development, making it a safer and more effective alternative to current options. Its unique approach of targeting mRNA rather than proteins further enhances its safety profile, distinguishing it from other therapies in the field.